⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL686974 | 0.82 | — | — | |
| SCHEMBL9683212 | 0.76 | — | — | |
| SCHEMBL12408557 | 0.76 | CA2 (0.46) | — | |
| SCHEMBL240710 | 0.76 | — | — | |
| SCHEMBL12225573 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL10904960 | 0.73 | — | — | |
| SCHEMBL14639934 | 0.73 | — | — | |
| SCHEMBL17626543 | 0.73 | LAP3 (0.47) | — | |
| SCHEMBL563336 | 0.73 | — | — | |
| SCHEMBL17626398 | 0.73 | LAP3 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20230355775-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-11739096-B2 | 5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer | PYRAMID BIOSCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230257827-A1 | CONJUGATES AND PREPARATION AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-11718637-B2 | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same | GILEAD SCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | TECHFIELDS PHARMA CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039375-A1 | Phosphorus-containing hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070208088-A1 | PQS: A NEW HYDROTROPE FOR SOLUBILIZING LIPOPHILIC COMPOUNDS IN WATER | ZYMES, LLC (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208086-A1 | UBIQUINONE ANALOGS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070203080-A1 | New Drug Delivery System for Crossing the Blood Brain Barrier | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-30 | — | — | US | disclosed |
| US-7244713-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7202223-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2007-02-01 | — | — | US | disclosed |
| US-7157434-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-02 | — | — | US | disclosed |